Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : TAK save search
Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
Published: 2021-03-03 (Crawled : 10:48) - investors.ovidrx.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 2.03%
H: 1.14%
C: 0.68%
OVID | $3.245 1.09% 1.08% 180K
|
Health Technology
|
| O: 58.45%
H: 1.28%
C: -13.86%
treatment commercialization children syndros dravet syndrome
Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-08-02 (Crawled : 14:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.36%
H: 0.75%
C: -0.18%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.02%
H: 0.21%
C: -0.12%
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
|
| O: 6.36%
H: 9.92%
C: 5.16%
vaccine trial approval sars-cov-2
Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies
Published: 2021-10-12 (Crawled : 14:15) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.21%
H: 0.14%
C: -1.05%
PSTX | $2.02 1.0% 0.99% 640K
|
Health Technology
|
| O: 5.26%
H: 0.5%
C: -4.57%
gene therapies collaboration research gene therapy therapy
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna
Published: 2022-05-31 (Crawled : 09:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -2.24%
H: 0.35%
C: -0.14%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: 5.09%
H: 0.0%
C: 0.0%
covid-19 japan vaccine authorization
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna
Published: 2022-05-31 (Crawled : 09:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -2.24%
H: 0.35%
C: -0.14%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: 5.09%
H: 0.0%
C: 0.0%
covid-19 japan vaccine authorization
Kadcyla Leads the Global Antibody Drug Conjugates Market with Extensive Use in Breast Cancer Treatment
Published: 2023-11-01 (Crawled : 18:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -1.46%
H: 3.67%
C: 3.26%
ZYME | $8.85 2.08% 2.03% 550K
|
Health Technology
|
| O: 1.14%
H: 0.42%
C: -0.7%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: -0.16%
H: 6.42%
C: 4.49%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
STRO | $3.635 -3.58% -3.71% 520K
|
Health Technology
|
| O: 0.39%
H: 3.86%
C: 3.86%
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: 5.09%
H: 5.48%
C: -1.27%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.47%
H: 1.88%
C: 1.78%
EXEL | $22.51 0.09% 0.09% 2.3M
|
Health Technology
|
| O: -2.62%
H: 1.17%
C: -1.66%
drug antibody breast cancer treatment global market
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
Published: 2023-11-02 (Crawled : 13:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 4.42%
H: 0.0%
C: 0.0%
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: 5.09%
H: 5.48%
C: -1.27%
financial results
Novel T-Cell Immunotherapies Market - Future Pipeline/Clinical Trial Analysis and Revenue Forecast Snapshot - Exclusive Report by InsightAce Analytic
Published: 2022-06-23 (Crawled : 08:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 1.56%
H: 0.73%
C: 0.44%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 4.14%
H: 0.0%
C: 0.0%
report t-cell trial market
Lymphoma Treatment Global Market to Reach $18.5 Billion by 2027 at a CAGR of 8.89%
Published: 2022-11-10 (Crawled : 13:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 2.34%
H: 2.51%
C: 2.29%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.09%
H: 0.48%
C: 0.4%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 1.22%
H: 0.01%
C: -1.7%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 3.59%
H: 1.37%
C: 1.16%
treatment global market
Neurocrine Biosciences Reports First Quarter 2023 Financial Results
Published: 2023-05-03 (Crawled : 12:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.36%
H: 0.57%
C: 0.18%
VYGR | $7.5 -0.66% -0.67% 520K
|
Health Technology
|
| O: 5.76%
H: 6.4%
C: 5.04%
NBIX M | $132.03 -0.39% -0.39% 560K
|
Health Technology
|
| O: 3.43%
H: 0.92%
C: -7.83%
financial results
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
Published: 2023-06-15 (Crawled : 14:20) - globenewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.31%
H: 0.78%
C: 0.69%
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: 2.46%
H: 9.6%
C: 5.6%
authorization cancer application
Irritable Bowel Syndrome Treatment Market to Surpass US$ 3,902.9 Million by 2030 - Coherent Market Insights
Published: 2022-06-24 (Crawled : 18:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: -0.5%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 6.71%
H: 0.0%
C: -0.1%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 4.33%
H: 0.0%
C: -2.44%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.36%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 2.38%
H: 0.0%
C: 0.0%
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: 5.78%
H: 13.91%
C: 13.78%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
IRWD | $7.94 4.47% 4.28% 2.5M
|
Health Technology
|
| O: 0.27%
H: 2.08%
C: 1.99%
treatment market
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
Published: 2023-11-02 (Crawled : 18:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.09%
H: 1.03%
C: 0.91%
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: 1.32%
H: 0.45%
C: -1.19%
MOR | News | $17.96 -0.5% -0.5% 180K
|
Health Technology
|
| O: 2.22%
H: 0.6%
C: -9.4%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.28%
H: 1.0%
C: -0.46%
presentation meeting
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
Published: 2022-12-13 (Crawled : 12:20) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 2.21%
H: 0.66%
C: -0.07%
ndi-0348 acquire therapeutics potential
Takeda to Acquire Nimbus Therapeutics’ Highly Selective, Allosteric TYK2 Inhibitor to Address Multiple Immune-Mediated Diseases
Published: 2022-12-13 (Crawled : 13:20) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 2.21%
H: 0.66%
C: -0.07%
acquire
Global Cancer Therapies Strategic Business Report 2023: Industry Focuses on New Approaches to Treat Cancer
Published: 2023-06-27 (Crawled : 01:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.95%
H: 0.19%
C: -0.32%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.19%
H: 0.11%
C: -1.46%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.01%
H: 0.16%
C: -0.32%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.03%
H: 0.12%
C: -0.24%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.91%
H: 0.56%
C: -0.5%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 2.15%
H: 1.18%
C: 0.43%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.06%
H: 0.46%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.21%
H: 0.42%
C: 0.13%
report business cancer treat global
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
Published: 2023-12-21 (Crawled : 00:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 2.05%
H: 0.29%
C: 0.0%
livtencity approval cytomegalovirus treatment china
Takeda Announces Acquisition of Own Shares - Oct 28, 2021
Published: 2021-10-28 (Crawled : 09:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 2.03%
H: 3.33%
C: 0.07%
acquisition
Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected Through Fiscal Year-End Driven by 14 Global Brands
Published: 2021-10-28 (Crawled : 09:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 2.03%
H: 3.33%
C: 0.07%
brands results growth liver
Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Report 2023: New Drug Launches and Growing Awareness Fuels $32 Billion Industry
Published: 2023-04-27 (Crawled : 00:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -1.13%
H: 0.3%
C: -0.48%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.79%
H: 0.89%
C: 0.72%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.12%
H: 0.58%
C: 0.55%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.25%
H: 0.97%
C: 0.31%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.96%
H: 1.59%
C: -0.54%
drug report treatment global growing market
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.